Press Release- 2013

Nes-Ziona, 12th June, 2013.Vaxil reports promising results from its VAXIL-002 follow-up clinical trial of ImMucin in multiple myeloma patients Read More

For further details see the attached PDF file.
Read More


 

Nes-Ziona, 9th April, 2013. Vaxil Reports Positive Results From a Phase I/II Clinical Trial Using Its Therapeutic Cancer Vaccine, ImMucin, In Patients With Multiple Myeloma Read More

For further details see the attached PDF file.
Read More


 

Nes-Ziona, 23th January, 2013. Vaxil Bio Ltd. announced a Collaboration with the University of Santiago de Compostela, Spain Read More

For further details see the attached PDF file.
Read More


 

 

Nes-Ziona, 21st January, 2013. Vaxil Bio Ltd. announced today that it is being moved up to Full Main Board Listing on the Tel Aviv Stock Exchange (TASE) Read More

For further details see the attached PDF file.
Read More